RecallRadar

FDA Drug recall D-135-2013

Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg)

On 2013-01-30 the FDA classified a Class I recall of Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg) by Genentech, citing presence of Particulate Matter: One lot of Bacteriostatic Water for Injection, USP diluent vials that were packed with Trastuzumab Kits for investigational use has the potential t….

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-135-2013
ClassificationClass I
Statusterminated
Initiated2012-07-30
Published2013-01-30
Last updated2026-09-13 11:51 UTC
CompanyGenentech
DistributionUS

Product

Trastuzumab Kit containing 1 vial Trastuzumab (nominal content: 440 mg); 1 20 mL multiple dose vial Bacteriostatic Water for Injection, USP (1.1% benzyl alcohol), Manufactured by Hospira, Inc., for Genentech, Inc., South San Francisco, CA 94080-4990, NDC 50242-903-69; and 1 Reconstitution Instructions per kit; Investigation Use only, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990.

Reason

Presence of Particulate Matter: One lot of Bacteriostatic Water for Injection, USP diluent vials that were packed with Trastuzumab Kits for investigational use has the potential to contain glass particulates.

Identifiers

code_infoLot #: 454138, Exp 07/14 (containing Trastuzumab Lot #: 886618, Exp 12/14; and Bacteriostatic Water for Injection, USP Lot #: 08-368-DK-01, Exp 07/14)

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-135-2013%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.